BMY

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.12
Percentage change 0.25	%

Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN NVS

| Held by: VTI VOO SCHD SPY IVV VTV XLV JEPI COWZ VYM

Scroll to Statements

Index	S&P 500	P/E	17.88	EPS (ttm)	2.66	Insider Own	0.10%	Shs Outstand	2.04B	Perf Week	2.04%
Market Cap	96.93B	Forward P/E	7.87	EPS next Y	6.05	Insider Trans	0.39%	Shs Float	2.03B	Perf Month	-2.38%
Enterprise Value	136.45B	PEG	0.25	EPS next Q	1.61	Inst Own	81.57%	Short Float	1.65%	Perf Quarter	-20.02%
Income	5.42B	P/S	2.03	EPS this Y	490.07%	Inst Trans	2.67%	Short Ratio	2.16	Perf Half Y	-17.42%
Sales	47.64B	P/B	5.57	EPS next Y	-10.85%	ROA	5.66%	Short Interest	33.61M	Perf YTD	-15.79%
Book/sh	8.54	P/C	8.23	EPS next 5Y	72.80%	ROE	31.99%	52W High	63.33 -24.79%	Perf Year	14.69%
Cash/sh	5.79	P/FCF	7.41	EPS past 3/5Y	- -	ROIC	8.35%	52W Low	39.35 21.04%	Perf 3Y	-40.45%
Dividend Est.	2.48 (5.22%)	EV/EBITDA	7.20	Sales past 3/5Y	1.36% 13.06%	Gross Margin	59.16%	Volatility	2.10% 1.97%	Perf 5Y	-18.13%
Dividend TTM	2.44 (5.12%)	EV/Sales	2.86	EPS Y/Y TTM	186.41%	Oper. Margin	22.93%	ATR (14)	1.05	Perf 10Y	-28.71%
Dividend Ex-Date	Jul 03, 2025	Quick Ratio	1.17	Sales Y/Y TTM	4.62%	Profit Margin	11.38%	RSI (14)	48.99	Recom	2.64
Dividend Gr. 3/5Y	6.38% 7.57%	Current Ratio	1.28	EPS Q/Q	120.45%	SMA20	-0.61%	Beta	0.37	Target Price	55.95
Payout	-	Debt/Eq	2.95	Sales Q/Q	-5.60%	SMA50	-0.53%	Rel Volume	0.79	Prev Close	47.51
Employees	34100	LT Debt/Eq	2.73	Earnings	Apr 24 BMO	SMA200	-11.90%	Avg Volume	15.53M	Price	47.63
IPO	Jul 05, 1929	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.43% 4.73%	Trades		Volume	12,289,095	Change	0.25%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Initiated	Piper Sandler	Overweight
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$55
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55
Nov-09-23	Initiated	Deutsche Bank	Hold	$55
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral	$68 → $54
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold	$55 → $53
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$60
Oct-20-23	Resumed	UBS	Neutral	$70 → $60

Show Previous Ratings

Today 06:50PM	Analyst Report: ConvaTec Group PLC (Morningstar Research)
Jul-01-25 05:45PM	Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note (Zacks)
09:35AM	Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth (Zacks)
09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
Jun-30-25 03:08PM	Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock? (Zacks)
09:50AM	Loading…
09:50AM	BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock? (Zacks)
08:42AM	AbbVie to buy Capstan for up to $2.1 billion in immunology push (Reuters)
Jun-27-25 10:31AM	FDA approves label updates for BMS CAR T cell therapies (Pharmaceutical Technology)
04:22AM	Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 \| Intensifying Competition as Key Players Advance Gene and Novel Therapies (GlobeNewswire)
01:57AM	Analyst Report: ConvaTec Group PLC (Morningstar Research)
Jun-26-25 10:05PM	U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibbs Cell Therapy Labels (Business Wire)
04:45PM	Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? (Investor's Business Daily)
09:47AM	Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE? (Zacks)
09:11AM	Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes (Investor's Business Daily)
08:15AM	Incyte replaces CEO Hoppenot with dealmaker Meury (BioPharma Dive)
02:09PM	Loading…
Jun-25-25 02:09PM	Cantor Maintains PriceTarget on BMY, Eyes Alzheimer's Trial as Key Catalyst (Insider Monkey)
10:02AM	Will New Drugs Enable BMY to Offset the Impact of Generic Competition? (Zacks)
09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
Jun-24-25 09:40AM	EXEL Stock Rises on Positive Data From Colorectal Cancer Study (Zacks)
09:00AM	Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock (Zacks)
Jun-23-25 12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
06:20AM	Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar? (Zacks)
Jun-20-25 02:09PM	The Top 5 Analyst Questions From Bristol-Myers Squibb's Q1 Earnings Call (StockStory)
11:51AM	CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech (Zacks)
10:01AM	Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now? (Zacks)
Jun-19-25 09:47AM	Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth? (Zacks)
09:10AM	How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks (Zacks)
07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
Jun-17-25 04:16PM	Bristol Myers Squibb Announces Dividend (Business Wire)
12:12PM	Loading…
12:12PM	Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly (Zacks)
11:20AM	Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal (Insider Monkey)
02:23AM	Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress (Insider Monkey)
Jun-16-25 05:45PM	Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
06:59AM	Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) (Business Wire)
04:25AM	2 Beaten-Down Dividend Stocks to Buy Right Now (Motley Fool)
Jun-15-25 05:47AM	Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial (Insider Monkey)
05:23AM	Jim Cramer on Bristol Myers: "We Need to See That Stock Back Up at $60" (Insider Monkey)
Jun-13-25 12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
10:00AM	Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump (Bloomberg)
09:47AM	BMY Focuses on Label Expansion of Drugs: Will This Revive Growth? (Zacks)
Jun-12-25 10:21AM	PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds (Zacks)
09:15AM	BMY Reports Positive Data on Sotyktu From Arthritis Study (Zacks)
06:59AM	Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader at EHA 2025 (Business Wire)
06:45AM	Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 (Business Wire)
Jun-11-25 10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:00AM	Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:59AM	Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis (Business Wire)
Jun-10-25 05:55PM	Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties (GlobeNewswire)
10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks)
Jun-09-25 05:45PM	Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider (Zacks)
09:50AM	Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
08:44AM	Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space (Zacks)
Jun-08-25 06:35AM	3 Stocks With Mouthwatering Dividends You Can Buy Right Now (Motley Fool)
Jun-06-25 09:41AM	Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)? (Insider Monkey)
09:16AM	BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? (Zacks)
06:20AM	Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar? (Zacks)
01:30AM	Despite Trade War, U.S. Drug Companies Turn to China for Key Cancer Treatments (Barrons.com)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks)
10:18AM	Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? (Zacks)
Jun-03-25 12:11PM	Bristol Myers Collaborates With BNTX for Oncology Candidate (Zacks)
06:42AM	Trump's Tax Bill Is Testing the Dollar. This Red Flag Matters More. (Barrons.com)
Jun-02-25 05:45PM	Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
03:01PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
01:38PM	Why BioNTech Stock Soared Today (Motley Fool)
12:10PM	Trump's steel tariffs, Bristol Myers-BioNTech, sports bet tax (Yahoo Finance Video)
11:45AM	M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal (Yahoo Finance Video)
11:39AM	Bristol Myers Joins Pharma's Hottest Horserace in $11.1B Deal With BioNTech (Barrons.com)
08:46AM	Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race (MarketWatch)
08:07AM	Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal (Bloomberg)
07:42AM	BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb (The Wall Street Journal)
06:45AM	BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types (Business Wire)
May-30-25 10:18PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
May-29-25 02:35PM	Bristol CEO: Pharma Tariffs Must Not Jeopardize Medicine Supplies (The Wall Street Journal)
11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks)
09:18AM	Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
May-28-25 09:00AM	Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:59AM	Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
06:55AM	Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications (Business Wire)
May-27-25 10:20AM	Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down (Zacks)
May-26-25 09:40AM	Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
May-23-25 09:57AM	EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort (Zacks)
09:29AM	Is it a Good Idea to Invest in Immunocore Stock Right Now? (Zacks)
May-22-25 05:05PM	Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline (Business Wire)
May-21-25 06:59AM	Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference (Business Wire)
May-19-25 01:29PM	Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects? (Zacks)
May-16-25 03:09PM	Jim Cramer On Bristol-Myers Squibb: "Waiting For It To Bottom" (Insider Monkey)
06:59AM	Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression 1% (Business Wire)
May-15-25 10:46AM	Jefferies not seeing significant impact to Merck, Bristol from draft guidance (TipRanks)
05:57AM	What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks (Motley Fool)
May-14-25 08:20PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research) -5.30%
09:00AM	Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know (Zacks)
May-13-25 05:05PM	Why Bristol-Myers Squibb Company (BMY) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom (Insider Monkey)
04:18PM	Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News (Investor's Business Daily)
06:20AM	Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar? (Zacks)
May-12-25 06:14PM	Drugmakers Spared Worst-Case Drug Pricing Scenario for Now (The Wall Street Journal)
06:14PM	Drugmakers Avoid Worst-Case Pricing Scenario for Now (The Wall Street Journal)
04:55PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '25	Option Exercise	0.00	8,040	0	8,040	Jun 04 05:37 PM
Hickey Benjamin	President, RayzeBio Org.	May 09 '25	Sale	38.01	97	3,702	0	May 13 07:03 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Apr 25 '25	Buy	47.58	4,250	202,215	83,513	Apr 29 06:14 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '25	Option Exercise	0.00	3,306	0	15,489	Apr 03 05:15 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '25	Option Exercise	0.00	11,255	0	20,148	Mar 12 09:39 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '25	Option Exercise	0.00	23,150	0	26,937	Mar 12 09:37 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Mar 10 '25	Option Exercise	0.00	20,423	0	22,339	Mar 12 09:35 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '25	Option Exercise	0.00	16,684	0	20,017	Mar 12 09:34 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '25	Option Exercise	0.00	7,164	0	8,546	Mar 12 09:32 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '25	Option Exercise	0.00	48,718	0	386,496	Mar 12 09:32 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '25	Option Exercise	0.00	7,446	0	7,920	Mar 12 09:31 PM
Holzer Phil M	SVP and Controller	Mar 10 '25	Option Exercise	0.00	7,140	0	17,870	Mar 12 09:31 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '25	Option Exercise	0.00	44,098	0	99,040	Mar 12 09:30 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '25	Option Exercise	0.00	7,588	0	11,626	Mar 12 09:29 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '25	Option Exercise	0.00	69,517	0	252,608	Mar 12 09:28 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '25	Option Exercise	0.00	60,034	0	152,898	Mar 12 09:27 PM
Hickey Benjamin	President, RayzeBio Org.	Mar 01 '25	Option Exercise	0.00	3,286	0	10,419	Mar 04 05:44 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Feb 20 '25	Buy	55.05	2,000	110,096	104,626	Feb 21 07:09 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Feb 14 '25	Buy	54.84	1,823	100,000	63,932	Feb 19 07:19 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '25	Option Exercise	0.00	10,078	0	10,858	Feb 04 07:05 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '25	Option Exercise	0.00	2,543	0	7,829	Feb 04 07:04 PM
Holzer Phil M	SVP and Controller	Nov 04 '24	Sale	55.62	700	38,930	11,760	Nov 05 05:53 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '24	Option Exercise	0.00	2,964	0	104,169	Nov 05 05:42 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Nov 01 '24	Buy	54.67	1,830	100,055	62,109	Nov 05 05:41 PM
Holzer Phil M	Officer	Nov 04 '24	Proposed Sale	55.62	700	38,930		Nov 04 11:20 AM
Gallman Cari	EVP, Corporate Affairs	Oct 02 '24	Option Exercise	0.00	4,558	0	6,667	Oct 03 06:33 PM
Gallman Cari	EVP, Corporate Affairs	Aug 01 '24	Option Exercise	0.00	1,061	0	2,493	Aug 05 06:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bristol-Myers Squibb Co

Upgrade your FINVIZ experience